Clinical Predictors of Severe Toxicity in Patients Treated with Combination Chemotherapy with Irinotecan and/or Oxaliplatin for Metastatic Colorectal Cancer: A Single Center Experience

Author：  

Publisher： Humana Press, Inc

ISSN： 1357-0560

Source： Medical Oncology, Vol.23, Iss.3, 2006-09, pp. : 347-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab Plus Irinotecan–Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens

By Yildiz Ramazan   Buyukberber Suleyman   Uner Aytug   Yamac Deniz   Coskun Ugur   Kaya Ali Osman   Ozturk Banu   Yaman Emel   Benekli Mustafa  

Cancer Investigation, Vol. 28, Iss. 1, 2010-01 ,pp. : 33-37

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice

By Rossi Luigi   Veltri Enzo   Zullo Angelo   Zoratto Federica   Colonna Maria   Di Seri Marisa   Longo Flavia   Mottolese Marcella   Giannarelli Diana   Ruco Luigi   Romiti Adriana   Barucca Viola   Adua Daniela   Tomao Silverio  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1193-1197

Future Medicine

Access to resources Recommend Favorite

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: A single center’s experience before and after their introduction

By Egreteau Joëlle   Boucher Eveline   Guibert Sophie   Jacquelinet Christian   Meunier Bernard   Boudjema Karim   Raoul Jean-Luc  

International Journal of Gastrointestinal Cancer, Vol. 35, Iss. 1, 2005-02 ,pp. : 69-76

Humana Press, Inc

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

By Park Sook   Hong Yong   Lim Hyeong-Seok   Seong Moon-Woo   Kong Sun-Young   Kim Sun   Park Young-Iee   Jung Kyung  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 953-964

Springer Publishing Company

Access to resources Recommend Favorite